TOMI CEO Dr. Halden Shane Conducts Interview with Proactive Investors

Rhea-AI Summary

TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) announced a positive business outlook in an interview with Proactive Investors. CEO Dr. Halden Shane highlighted approximately $3.5 million in orders for Custom Engineered Systems during the first quarter, with numerous projects in progress. The company possesses over $5 million in cash and hard assets exceeding $10 million. Dr. Shane anticipates a strong year for sales across all TOMI products, driven by a robust first quarter performance.

Positive

• Received orders worth approximately $3.5 million for Custom Engineered Systems.
• Strong balance sheet with over $5 million in cash and no debt besides trade payables.
• Hard assets valued at over $10 million.

Negative

• None.

FREDERICK, Md., April 25, 2022 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company that specializes in disinfection and decontamination through the utilization of its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced an interview with Proactive Investors in which Dr. Halden Shane, CEO, discussed the Company’s business outlook.

Interested parties can access the interview at this link.

During the interview, Dr. Shane discussed the Company’s business model and strong preliminary first quarter results, including receiving approximately $3.5 million in orders for its Custom Engineered Systems (“CES”), with many more projects underway. He also discussed TOMI’s strong balance sheet with over $5 million in cash, no debt other than ordinary trade payables, and hard assets of over $10 million. Dr. Shane believes that 2022 will be a very good year for sales in relation to all the Company’s products, with a strong first quarter boding well for the rest of 2022.

TOMI™ Environmental Solutions, Inc.: Innovating for a safer world^®   

TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology^® (BIT^™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT^™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP^™). Represented by the SteraMist^® brand of products, iHP^™ produces a germ-killing aerosol that works like a visual non-caustic gas. 
  
TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. 
  
TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. 
  
For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contain forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to anticipated financial performance and operating results, including expected result for the March quarter in 2022; expected growth in sales and market demand; and the trading price of common stock. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.

INVESTOR RELATIONS CONTACT:

John Nesbett/Jennifer Belodeau

IMS Investor Relations

tomi@imsinvestorrelations.com